Darja Urlep1,2, Evgen Benedik3,4, Jernej Brecelj1,2, Rok Orel1,2. 1. Department of Gastroenterology, Hepatology and Nutrition, University Children's Hospital Ljubljana, Bohoričeva 20, 1000, Ljubljana, Slovenia. 2. Faculty of Medicine, University of Ljubljana, Vrazov trg 2, 1000, Ljubljana, Slovenia. 3. Department of Gastroenterology, Hepatology and Nutrition, University Children's Hospital Ljubljana, Bohoričeva 20, 1000, Ljubljana, Slovenia. evgen.benedik@gmail.com. 4. Biotechnical Faculty, University of Ljubljana, Jamnikarjeva ulica 101, 1000, Ljubljana, Slovenia. evgen.benedik@gmail.com.
Abstract
The aim of this study was to evaluate rates of clinical remission, endoscopic remission, and mucosal healing after a 6-week treatment period with partial enteral nutrition (PEN) and to compare them to those obtained by standard exclusive enteral nutrition (EEN) treatment in children with active Crohn's disease (CD). Twenty-five patients with active CD (median age 13.6 years, range 3.6-18.0) were recruited to either PEN (n = 12) or EEN (n = 13) treatment groups. The PEN group received 75% of their dietary needs from a polymeric formula plus one meal per day from an anti-inflammatory diet (AID). Patients were assessed at weeks 0, 1, 3, and 6 using clinical and laboratory parameters. Endoscopic assessment was performed at induction and week 6. On intention to treat analysis, clinical remission (Pediatric CD Activity Index < 10) was achieved in 69.2% and 75.0% of EEN and PEN patients, respectively (p = 0.999). The endoscopic remission (Simple Endoscopic Score for CD (SES-CD) ≤ 2) rates were 45.5% in both groups, while mucosal healing rates (SES-CD = 0) were 45.5% with EEN and 27.3% with PEN (p = 0.659). Conclusion: The results of our prospective pilot study suggest that PEN, allowing one meal from AID, could be as effective as EEN in inducing clinical and endoscopic remission in children with active CD. However, larger randomized controlled studies are warranted to confirm our findings.Trial registration: This clinical trial was registered under the number ClinicalTrials.govidentifier: NCT03176875.What is Known:• Exclusive enteral nutrition is a first-line treatment in active pediatric Crohn's disease; however, patients often find it difficult to adhere to.• Exclusive enteral nutrition is more effective than corticosteroids in achieving mucosal healing.What is New:• This is the first prospective study on partial enteral nutrition in active pediatric Crohn's disease, evaluating not only clinical, but also endoscopic remission.• A novel approach of partial enteral nutrition that allows one meal per day from an anti-inflammatory diet was as effective as exclusive enteral nutrition in inducing clinical and endoscopic remission in active Crohn's disease.
The aim of this study was to evaluate rates of clinical remission, endoscopic remission, and mucosal healing after a 6-week treatment period with partial enteral nutrition (PEN) and to compare them to those obtained by standard exclusive enteral nutrition (EEN) treatment in children with active Crohn's disease (CD). Twenty-five patients with active CD (median age 13.6 years, range 3.6-18.0) were recruited to either PEN (n = 12) or EEN (n = 13) treatment groups. The PEN group received 75% of their dietary needs from a polymeric formula plus one meal per day from an anti-inflammatory diet (AID). Patients were assessed at weeks 0, 1, 3, and 6 using clinical and laboratory parameters. Endoscopic assessment was performed at induction and week 6. On intention to treat analysis, clinical remission (Pediatric CD Activity Index < 10) was achieved in 69.2% and 75.0% of EEN and PEN patients, respectively (p = 0.999). The endoscopic remission (Simple Endoscopic Score for CD (SES-CD) ≤ 2) rates were 45.5% in both groups, while mucosal healing rates (SES-CD = 0) were 45.5% with EEN and 27.3% with PEN (p = 0.659). Conclusion: The results of our prospective pilot study suggest that PEN, allowing one meal from AID, could be as effective as EEN in inducing clinical and endoscopic remission in children with active CD. However, larger randomized controlled studies are warranted to confirm our findings.Trial registration: This clinical trial was registered under the number ClinicalTrials.govidentifier: NCT03176875.What is Known:• Exclusive enteral nutrition is a first-line treatment in active pediatric Crohn's disease; however, patients often find it difficult to adhere to.• Exclusive enteral nutrition is more effective than corticosteroids in achieving mucosal healing.What is New:• This is the first prospective study on partial enteral nutrition in active pediatric Crohn's disease, evaluating not only clinical, but also endoscopic remission.• A novel approach of partial enteral nutrition that allows one meal per day from an anti-inflammatory diet was as effective as exclusive enteral nutrition in inducing clinical and endoscopic remission in active Crohn's disease.
Authors: Dale Lee; Robert N Baldassano; Anthony R Otley; Lindsey Albenberg; Anne M Griffiths; Charlene Compher; Eric Z Chen; Hongzhe Li; Erin Gilroy; Lisa Nessel; Amy Grant; Christel Chehoud; Frederic D Bushman; Gary D Wu; James D Lewis Journal: Inflamm Bowel Dis Date: 2015-08 Impact factor: 5.325
Authors: Salvatore Oliva; Mike Thomson; Lissy de Ridder; Javier Martín-de-Carpi; Stephanie Van Biervliet; Christian Braegger; Jorge Amil Dias; Sanja Kolacek; Erasmo Miele; Stephan Buderus; Jiri Bronsky; Harland Winter; Víctor Manuel Navas-López; Amit Assa; Sonny K F Chong; Nadeem Ahmad Afzal; Francoise Smets; Ron Shaoul; Séamus Hussey; Dan Turner; Salvatore Cucchiara Journal: J Pediatr Gastroenterol Nutr Date: 2018-09 Impact factor: 2.839
Authors: Fabian Schnitzler; Herma Fidder; Marc Ferrante; Maja Noman; Ingrid Arijs; Gert Van Assche; Ilse Hoffman; Kristel Van Steen; Séverine Vermeire; Paul Rutgeerts Journal: Inflamm Bowel Dis Date: 2009-09 Impact factor: 5.325
Authors: Frank M Ruemmele; Jeffrey S Hyams; Anthony Otley; Anne Griffiths; Kaija-Leena Kolho; Jorge Amil Dias; Arie Levine; Johanna C Escher; Jan Taminiau; Gabor Veres; Jean-Frederic Colombel; Séverine Vermeire; David C Wilson; Dan Turner Journal: Gut Date: 2014-05-12 Impact factor: 31.793
Authors: Charlotte M Verburgt; Mohammed Ghiboub; Marc A Benninga; Wouter J de Jonge; Johan E Van Limbergen Journal: Nutrients Date: 2021-01-13 Impact factor: 5.717
Authors: Lara Hart; Charlotte M Verburgt; Eytan Wine; Mary Zachos; Alisha Poppen; Mallory Chavannes; Johan Van Limbergen; Nikhil Pai Journal: Nutrients Date: 2021-12-21 Impact factor: 5.717